Valuation: IDEAYA Biosciences, Inc.

Market Cap 3.6B 3.2B 2.99B 2.72B 5.14B 347B 5.18B 36.2B 14.04B 177B 13.53B 13.24B 569B P/E 2026 *
-8.14x
P/E 2027 * -9.09x
Enterprise Value 2.61B 2.32B 2.16B 1.97B 3.72B 252B 3.76B 26.25B 10.18B 128B 9.81B 9.6B 412B EV / Sales 2026 *
63.6x
EV / Sales 2027 * 21.2x
Free-Float
97.81%
Yield 2026 *
-
Yield 2027 * -
09-14 IDEAYA Biosciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:00 AM
09-10 IDEAYA Biosciences, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 01:40 PM
09-09 IDEAYA Biosciences, Inc. and Servier Dose First Patient in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Uveal Melanoma CI
09-09 Ideaya Biosciences, Servier Dose First Patient in Phase-3 Primary Uveal Melanoma Trial MT
08-31 IDEAYA Biosciences Announces Successful FDA Type C Meeting For IDE849 DLL3 TOP1 ADC On Phase 3 Registrational Trial Design For Potential Accelerated And Full Approval In Extensive Stage Small Cell Lung Cancer CI
08-31 IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy MT
08-19 Ideaya Biosciences, Genentech Partner for Pancreatic Cancer Trial MT
08-19 IDEAYA Biosciences, Inc. Enters Clinical Collaboration With Genentech To Evaluate IDE892 In Combination With RG6620 In MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer CI
08-07 Certain Pre-Funded Warrants of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. CI
08-07 Certain Common Stock of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. CI
08-07 Certain Stock Options of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. CI
08-04 Wedbush Adjusts Price Target on IDEAYA Biosciences to $60 From $58, Maintains Outperform Rating MT
08-04 IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises MT
1 day-1.19%
1 week+1.83%
Current month-2.76%
1 month-6.53%
3 months-0.77%
6 months+14.11%
Current year+8.07%
1 week 36.1
Extreme 36.1
39.39
1 month 35.59
Extreme 35.59
40
Current year 26.81
Extreme 26.81
42.68
1 year 26.05
Extreme 26.05
42.68
3 years 13.45
Extreme 13.45
47.74
5 years 8.14
Extreme 8.14
47.74
10 years 2.95
Extreme 2.95
47.74
Manager TitleAgeSince
Chief Executive Officer 51 2015-05-31
Director of Finance/CFO 51 2025-04-30
Chief Tech/Sci/R&D Officer 59 2022-11-20
Director TitleAgeSince
Chairman 51 2026-06-16
Chairman 67 -
Director/Board Member 71 2015-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Exercice

Controller/Auditor

28,650 0.0327%
6/16/26 Free

Director

20,000 0.0228%
3/2/26 Buy

Director

50,000 0.0570%
Change 5-day change 1-year change 3-year change Capi.($)
-1.19%+1.83%+35.17%+46.39% 3.6B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.32%-0.35%+50.89%+120.32% 39.41B
Weighted average by Cap. +0.11%-0.82%+56.76%+137.42%

Financials

2026 *2027 *
Net sales 41.1M 36.5M 34.03M 31.02M 58.56M 3.96B 59.09M 413M 160M 2.02B 154M 151M 6.48B 120M 106M 99.17M 90.41M 171M 11.53B 172M 1.2B 466M 5.88B 450M 440M 18.89B
Net income -431M -383M -357M -326M -615M -41.55B -620M -4.33B -1.68B -21.18B -1.62B -1.58B -68.08B -417M -371M -345M -315M -594M -40.17B -600M -4.19B -1.62B -20.48B -1.57B -1.53B -65.82B
Net Debt -991M -880M -821M -748M -1.41B -95.45B -1.43B -9.95B -3.86B -48.66B -3.72B -3.64B -156B -1.07B -948M -884M -806M -1.52B -103B -1.53B -10.72B -4.16B -52.4B -4.01B -3.92B -168B
Logo IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Employees
145
Date Price Change Volume
26-10-02 US$37.36 -1.19% 579,047
26-10-01 US$37.81 -1.59% 712,274
26-09-30 US$38.42 +1.48% 1,016,445
26-09-29 US$37.86 -0.94% 815,446
26-09-28 US$38.22 +4.17% 1,053,735
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
37.36USD
Average target price
52.75USD
Spread / Average Target
+41.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDYA Stock